Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xaluritamig + abiraterone
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Xaluritamig + abiraterone** is an investigational combination therapy being studied for metastatic castration-resistant prostate cancer (mCRPC). Xaluritamig (AMG 509) is a bispecific T-cell engager that targets the six-transmembrane epithelial antigen of the prostate 1 (**STEAP1**) on cancer cells and CD3 on T-cells, directing immune-mediated cytotoxicity against STEAP1-positive prostate cancer cells. Abiraterone is a widely used oral androgen biosynthesis inhibitor that blocks CYP17A1, reducing androgen production and suppressing tumor growth. The combination is being studied for potential synergistic anti-tumor effects in advanced prostate cancer, aiming to improve immune-mediated lysis of tumor cells in the context of androgen deprivation[1][2][5].
- Other names
- xaluritamig + abiraterone
02
Targets
CD3 (T-cell surface glycoprotein CD3)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)
Beyond the preview
Go deeper on xaluritamig + abiraterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xaluritamig + abiraterone.